RHYTHM PHARMACEUTICALS, INC. (RYTM)

Import this data to Google Sheets with:

=jivedata("RYTM","financials")

Full statements spill as a table. For one cell: =jivedata("RYTM","Revenue") or =jivedata("RYTM","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

RHYTHM PHARMACEUTICALS, INC.

RYTM • CIK 0001649904

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Excluding Assessed Tax	$77,428	$130,126	$189,757	$239,918
Operating Income (Loss)	$-184,357	$-265,503	$-192,016	$-200,629
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$-184,114	$-260,256	$-196,042	$-204,277
Income Tax Expense (Benefit)	$564	$346	$497	$1,069
Net Income (Loss) Attributable to Parent	$-184,678	$-260,602	$-196,539	$-205,346
Net Income (Loss) Available to Common Stockholders, Basic	—	$-264,572	$-201,917	$-210,222
Weighted Average Number of Shares Outstanding, Basic	57,673,128	60,995,204	64,984,361	69,896,007
Cost of Goods and Services Sold	$9,302	$13,368	$19,492	$26,389
Research and Development Expense	$134,951	$237,957	$167,340	$173,212
Selling, General and Administrative Expense	$117,532	$144,304	$194,941	$240,946
Costs and Expenses	$261,785	$395,629	$381,773	$440,547
Other Nonoperating Income (Expense)	$190	$2,239	$1,264	$-354
Derivative, Gain (Loss) on Derivative, Net	—	$8,900	$0	$0
InterestExpenseNonoperating	—	$20,603	$20,583	$18,480
Investment Income, Net	$13,945	$14,711	$15,293	$15,186
Nonoperating Income (Expense)	$243	$5,247	$-4,026	$-3,648
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	$-140	$2	$-1,261	$1,638
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax	$366	$-175	$504	$-302
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$-184,452	$-264,746	$-202,674	$-206,717

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$60,081	$89,137	$54,301	$65,614
Short-term Investments	$215,765	$231,428	$334,648	$265,283
Property, Plant and Equipment, Net	$1,341	$632	$1,104	$103
Accounts Receivable, after Allowance for Credit Loss, Current	$14,867	$18,512	$26,081	$40,408
Operating Lease, Right-of-Use Asset	$781	$3,477	$3,049	$2,817
Inventory, Net	$8,624	$18,741	$25,753	$30,517
Finite-Lived Intangible Assets, Net	$7,028	$6,174	$5,319	$4,892
Prepaid Expense and Other Assets, Current	$8,931	$16,382	$26,133	$24,741
Restricted Cash	$328	$464	$522	$603
Assets, Current	$308,268	$374,200	$466,916	$426,563
Other Long-term Investments	$14,999	$7,326	$3,286	$2,288
Assets	$332,745	$392,273	$480,196	$437,266
Temporary Equity, Carrying Amount, Attributable to Parent	—	$142,820	$130,957	$114,318
Accounts Payable, Current	$4,885	$12,328	$13,947	$16,165
Accrued Liabilities, Current	$48,262	$62,658	$83,855	$83,855
Other Liabilities, Current	—	$37,704	$0	$0
Deferred Revenue, Current	$1,286	$1,286	$194	$0
Long-term Debt, Current Maturities	—	$1,541	$7,296	$12,703
Operating Lease, Liability, Current	$770	$770	$650	$703
Liabilities, Current	$55,203	$115,517	$105,942	$123,587
Long-term Debt, Excluding Current Maturities	—	$108,269	$100,886	$93,399
Operating Lease, Liability, Noncurrent	$490	$3,938	$3,342	$2,979
Derivative Liability	$1,150	$1,150	$0	$0
Liabilities	$162,986	$227,724	$210,170	$219,965
Common Stock, Value, Issued	$59	$61	$67	$69
Additional Paid in Capital	$1,064,302	$1,177,045	$1,491,675	$1,560,640
Accumulated Other Comprehensive Income (Loss), Net of Tax	$134	$-39	$-796	$-912
Retained Earnings (Accumulated Deficit)	$-894,736	$-1,155,338	$-1,351,877	$-1,456,814
Stockholders' Equity Attributable to Parent	$169,759	$21,729	$139,069	$102,983
Common Stock, Shares Authorized	120,000,000	120,000,000	120,000,000	120,000,000
Common Stock, Shares, Issued	59,426,559	62,390,654	67,205,321	68,816,868

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-184,678	$-260,602	$-196,539	$-205,346
Net Cash Provided by (Used in) Operating Activities	$-136,157	$-113,879	$-115,675	$-105,348
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$-142	$2	$87	$599
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-67,596	$29,192	$-34,778	$-69,896
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$60,409	$89,601	$54,823	$11,002
Share-based Payment Arrangement, Noncash Expense	$32,553	$39,682	$66,818	$87,231
Payments to Acquire Short-term Investments	$354,918	$268,313	$348,669	$373,879
Proceeds from Maturities, Prepayments and Calls of Short-term Investments	$354,967	$260,640	$252,469	$269,897
Payments to Acquire Intangible Assets	$5,667	$40,500	$40,000	$40,000
Payments to Acquire Property, Plant, and Equipment	$47	$47	$953	$953
Net Cash Provided by (Used in) Investing Activities	$-5,665	$-48,173	$-137,153	$-144,935
Increase (Decrease) in Derivative Liabilities	$-190	$-1,420	$-910	$70
Derivative, Gain (Loss) on Derivative, Net	—	$8,900	$0	$0
Other Noncash Income (Expense)	—	—	$-90	$-755
Repayments of Long-term Debt	$7,398	$12,900	$19,917	$22,165
Proceeds from Issuance Initial Public Offering	—	—	$188,657	$188,657
Proceeds from Stock Options Exercised	$7,468	$15,976	$13,604	$21,029
Proceeds from Stock Plans	$1,053	$1,270	$1,584	$1,981
Proceeds from Issuance of Common Stock	$48,875	$39,146	$34,035	$1
Proceeds from Issuance of Long-term Debt	$24,370	$24,370	$0	$0
Proceeds from Issuance of Redeemable Convertible Preferred Stock	—	$138,850	$0	$0
Net Cash Provided by (Used in) Financing Activities	$74,368	$191,242	$217,963	$179,788
Noncash or Part Noncash Acquisition, Value of Liabilities Assumed	—	$33,669	$0	$0
Stock Issued	—	—	$0	$0
Temporary Equity, Accretion of Dividends	—	$3,970	$5,378	$4,876
Increase (Decrease) in Accounts Receivable	$8,643	$3,645	$7,570	$14,751
Increase (Decrease) in Inventories	$5,707	$10,117	$7,474	$12,806
Increase (Decrease) in Prepaid Expense and Other Assets	$-2,876	$5,524	$6,327	$-5,995
Increase (Decrease) in Deferred Revenue	$-148	$-148	$-1,092	$0
Increase (Decrease) in Other Noncurrent Assets	$-1,656	$-7,943	$397	$5,488
Increase (Decrease) in Accounts Payable and Accrued Liabilities	$14,773	$21,918	$21,892	$23,108

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("RYTM","financials")

Full statements spill as a table. For one cell: =jivedata("RYTM","Revenue") or =jivedata("RYTM","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.